Medigene to Present at H.C. Wainwright's Virtual Cell Therapy Conference

Progress in immuno-oncology is a constant companion in modern medicine, and companies like Medigene AG are in the spotlight when it comes to revolutionary therapeutic approaches. This pioneering spirit is once again evident, as the company has announced that it has confirmed its presence at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26th. Medigene is committed to researching and developing T-cell-based immunotherapies for the treatment of solid tumors and will bring its expertise to this conference. Participating in the conference provides Medigene with a platform to present its innovative approaches to an international audience of specialists. Special focus will be on the leading TCR-T program MDG1015, which is dedicated to meeting high standards of safety, efficacy, and durability to shape the treatment of solid tumors in new dimensions. With its proprietary end-to-end platform approach, Medigene positions itself as a leading developer of differentiated T-cell therapies. Interested investors and stakeholders will have the opportunity during the conference to learn about Medigene's strategy, clinical progress, and future prospects directly from members of the management team in a fireside chat as well as in personal virtual discussions. For more information about Medigene and its ambitious projects, the company refers to its website and is open to dialogue with those interested in deepening understanding and interest in modern immunotherapies.